Description: PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
Home Page: www.pcibiotech.com
UllernchaussEen 64
Oslo,
0379
Norway
Phone:
47 67 11 54 00
Officers
| Name | Title |
|---|---|
| Mr. Ronny Skuggedal | CEO & CFO |
| Dr. Anders Høgset | Chief Scientific Officer |
| Ms. Kristin Eivindvik | Chief Devel. Officer |
| Lucy Wabakken | Acting CDO |
Exchange: OL
Country: NO : Norway
Currency: Norwegian Krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4376 |
| Price-to-Sales TTM: | 18.7378 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |